


SUPPLEMENTARY INFORMATION


Supplementary figures

Supplementary Fig. 1 Kaplan-Meier estimates of PFS for patients receiving ixazomib with (A) high-risk cytogenetic abnormalities, and B) expanded high-risk cytogenetic abnormalities, compared with standard-risk abnormalities.




CI confidence interval; HR hazard ratio; PFS progression-free survival.

Supplementary Fig. 2 Kaplan-Meier estimates of PFS for patients with del(17p) vs standard-risk cytogenetic abnormalities receiving placebo-based therapy.



CI confidence interval; *HR* hazard ratio; *PFS* progression-free survival.

Supplementary Fig. 3 Kaplan-Meier estimates of PFS for patients with t(14;16) cytogenetic abnormality receiving ixazomib- vs placebo-based therapy.



CI confidence interval; *HR* hazard ratio; *PFS* progression-free survival.